Yes.

Caryle 40/40/37

Roberta Innarella <[log in to unmask]> wrote:
Did anyone else receive an e-mail like this?
Roberta
From time to time, neurologists, caregivers, and MSA or Parkinson’s disease
sufferers, their friends and families, provide us with the addresses of those
they believe may be interested in receiving our research updates and
newsletters on Neuronal Regeneration. (Also called Neurogenesis).
They have noticed that our research project presents innovative approaches
to treat a number of neurodegenerative disorders. They have also observed a
direct improvement in MSA and PD patients who are following our Neurogenic
Intervention Programme. They would like to share research results, in order to
substantiate the evidence and rationale behind the use of neurogenic
intervention programmes. Further research in neuroscience, clinical data and medical
reports are required.
Please let us know if you are interested in this subject and if you would
like to receive or contribute with information about this specific type of
research.
We apologise if the above subject is not one of your particular concern. If
this is the case, please let us know in order that we can immediately erase
your details from our mailing list.
On the other hand, if you are interested in this subject, we are pleased to
inform you about our web site address:
_www.br13.com_ (http://www.br13.com/)
where you can find general information about this research.
For more specific research information, with references relating to
neurogenesis and also to the aetiology, nutritional and environmental factors
concerning MSA and PD, please visit our web site:
_www.shydrager.com_ (http://www.shydrager.com/)

Every year, we produce a video documentary and printed enclosures, showing
the experiences and responses of Parkinson’s disease and MSA sufferers who
have followed our neurogenic dietary intervention programme for some time.
These documentaries are sent, free of charge, to doctors, caregivers,
clinics and also to patients who are really interested in viewing the practical
results of this type of research. Please let us know if you would like to
receive this material that is available on DVD or VHS, and where it should be sent.

Since the year 2002, when we first published the six basic stages on which
our Neurogenic Dietary Intervention Programme is based, we have received
encouraging feedback from doctors and scientists world-wide.
For example, in relation to Stage 1 of the Neurogenic Diet, we received
various medical reports indicating that they obtained substantial improvements
when a re-adjustment of PD medication was combined with the use of an
appropriate nutritional intervention.
A number of patients who personally researched Stage 4 of the Neurogenic
Diet, came across with findings that led them to the discovery of what was the
main causative factor of their own disease. Then, by strictly avoiding further
contact with this specific causative agent, they found that their symptoms,
that had affected them for years, started now gradually to disappear.
Also, a large number of patients benefited when following Stage 6 of The
Neurogenic Diet. This relates to the importance of an appropriate exercise
programme to allow the enhancement of neuronal regeneration. A number of physical
therapists developed special exercise programmes, aiming to enhance
neurogenic activity in Parkinson’s disease and in MSA. Soon after, they were able to
report that, thanks to this exercise programme, patients were able to reduce
their need for their medication by more than 30%.
in the year 2002, neuroscientists from our team suggested, that neurogenesis
can also occur in the dopaminergic system in the human brain . They observed
that Parkinson’s Disease and MSA patients, who followed the neurogenic
programme, could gradually delay the use of their first dose of PD medication.
Some patients were surprised to see that, instead of needing to start the first
dose at 7 am, they were able to function normally, without any medication
until 10 am. Later on, they realised they could delay it until 1 pm. Some
patients were even able to postpone it until late in the afternoon.
This was a very clear indication that these patients had been able to
restore their own neuronal capabilities to produce brain neurotransmitters like
dopamine, without the need of a direct external source, precursor or dopamine
agonist.
Now, in 2004, it has finally been confirmed in a number of medical and
scientific research publications, that neurogenesis can also take place in
dopaminergic neurons in the substantia nigra in the adult mammalian brain. These
areas are the main neuronal systems affected in Parkinson’s Disease and MSA-P.
The main objective of our research newsletter is the dissemination of
scientific information in relation to neurogenesis. We try to present this precious
scientific knowledge, in the clearest way, in order that a better
understanding about it, be utilised to improve the quality of life of Parkinson’s
Disease and MSA sufferers.
As an example of one of our previous newsletters and documentaries, we are
pleased to enclose below, part of the script of the: "Documentary on
Neurogenesis, Year 2003"
Thank you for your time
Nutritional Medicine Research.
_www.br13.com_ (http://www.br13.com/)
_www.shydrager.com_ (http://www.shydrager.com/)
e-mail: [log in to unmask]
24 Hour Telephone Help Line and Information:
In the USA: 520 750 6466
All Other countries: 00-44 7930 915 588
TEXT FROM VIDEO SCRIPT
for the Documentary on
NEUROGENESIS RESEARCH
TITLE:
ORIGINAL HOME-VIDEO CLIPS SHOWING THE GENUINE PERSONAL EXPERIENCES OF
PARKINSON’S DISEASE AND MSA SUFFERERS.
To assess the degrees of neuronal activity which can be induced through a
specific type of intervention, the following suggestions are indicated for
Parkinson’s disease and MSA patients:
1. –The assessment must be done in the morning. Patients must be free of
Parkinson’s disease medication and of any medicinal extract for at least 18 to
24 hours.
2. - To determine the degree of advancement of the disease, find out which
movements or activities are the most difficult to perform, before taking the
early morning extract or the prescribed PD drugs.
3. - The ability to perform each task needs to be evaluated. This
examination measures, for example, the ability to stand up from a chair, getting out of
bed, walking, opening doors, dressing, writing, taking a bath, etc.
4. - DNA repair and neuronal regeneration are slow processes therefore, to
be able to observe any external changes, the evaluation tests are usually
performed at 3 monthly intervals.
5. - The ability to improve performance in any of the above activities will
indicate to us the degree in which the neurogenic intervention has succeeded.

6. - Most neurological examinations and disability scales are designed to
test the ability of a drug to improve mobility for a limited number of hours,
following the taking of a specific drug. Here, instead, we test the ability of
a treatment to regenerate Neurons. Therefore, tests need to be taken at a
time when no drugs or extracts had been used, whatsoever, for at least 18
hours.
7. – An improvement in the performance of any of the above activities will
indicate to us that enrichment in brain transmitter biosynthesis has occurred
during sleeping hours. This endogenous enhancement of neurotransmitter
biosynthesis can only occur as a result of an increase in the number of active
brain dopaminergic neurons.
The first patient shown on our video documentary is an 89 year old lady,
diagnosed with Parkinson’s disease 4 years ago.
A medical history, and report, with further details, is available for
doctors interested in receiving additional information on this woman.
In 1999 she was diagnosed with Parkinson’s disease and prescribed the drug
Sinemet 25/100. She tried it for a short time, soon after; this drug had to be
discontinued due a bad reaction to it and to undesirable side effects.
In April 1999, she started our neurogenic dietary intervention programme,
which resolved efficiently her gait disturbance and did not cause her any side
effects at all.
After one year of using the neurogenic diet, she was able to walk
independently without the aid of a cane. At the time of diagnosis, she suffered from a
moderate bradykinesia. One year later, there was no apparent sign of a
bradykinetic problem at all.
During the second year on the neurogenic diet, she became totally
independent in the morning. She was able to prepare breakfast, dress herself and go out
for a walk without any assistance.
After four years on the neurogenic diet, the disease did not show any
progression. Instead, there was an apparent disappearance of many of the initial
symptoms that lead to the diagnosis of Parkinson’s disease in 1999.
In December 2002, at her fourth year on the neurogenic programme, the woman’
s daughter filmed a tape for us and her doctor to show that her mother was
now able to perform exercises which were impossible to do a year earlier.
This exercise consists of lying on the floor by herself and lifting herself
up from the floor, without assistance. This demonstration was filmed at 10
am. The last time she had taken her extract was the previous day at 6 am, that
is, 28 hours earlier.
The exercise that this lady managed to perform and showed to us is not only
a difficult exercise to perform by any Parkinson’s disease patient, but also
by anyone at the age of 89.
The exercise that she had done is a difficult exercise for anyone at the age
of 89, but particularly for anybody suffering for Parkinson disease.
The second patient, presented in this video, had been suffering from
Parkinson’s disease for 20 years.
She is now 78 years old. She is 11 years younger than the previous patient
shown in this video. She took Sinemet 25/100, four to six times a day, during
the first 15 years she had the disease. During the period she was taking
Sinemet, she had sensitive reactions against it, which made her suffer from a
number of side effects, over many years.
She started on the neurogenic diet in 1997, that is, almost 5 years ago.
When she started our treatment, she had been unable to walk for the previous two
years and had to make use of a wheelchair during the day.
With the introduction of the neurogenic diet, Sinemet was discontinued and
replaced by our extracts. This approach allowed her to obtain improvements in
her mobility and the side effects; she had been suffering, gradually
disappeared.
With the help of the extracts, she was able to perform essential movements
without having any form of dyskinesia, freezing episodes and "off periods".
However, our treatment could not enhance a proper neurogenic activity, mainly
because, being almost all day in a wheelchair, she had not been able to
perform any form of exercise or any major muscular activity; these are essential
factors needed to activate the processes of neurogenesis.
It is important to note that what occurred with this patient, is the
opposite of what happened to the 89 year old patient shown previously who has been
able to take one hour walks every day. In relation to this, she made the
following comment in her home-made video: "If you don’t walk at all, then you can’
t walk." This personal observation represents her feelings after realising
that the more she can walk and exercise, the better her mobility. Whenever she
stops walking, she realises that it becomes harder to start again.
The experiences of these two patients, confirmed to us, that exercise and
physical activity are the two main factors required for neurogenic processes to
take place.
The use of our dietary intervention and extracts can only enhance the
process of neurogenesis when the patient is able to perform a certain amount of
exercise and physical activity.
A number of areas of the brain are affected by MSA.
This has led to different varieties of MSA receiving different names,
depending on which area of the brain has predominant involvement.
When a patient initially has rigidity (stiffness) and slowness in initiating
movements (bradykinesia) which is out of proportion to tremour, this MSA
form has been called striatonigral degeneration, involving communication between
nerve cells in the striatum and midbrain. This is the form of MSA which has
been diagnosed to the third patient shown in the video. It is also called
MSA-P, because it resembles the symptoms of Parkinson’s disease.
This patient was diagnosed two years ago, as having Parkinson’s disease.
Soon after, her neurologist realised that she had developed MSA-P.
This is a Multiple System Atrophy of the Striatonigral Degeneration Type.
The patient was experiencing serious difficulties in breathing, walking, had
a very poor balance, dryness of mouth, difficulties in swallowing,
intermittent sleep, constipation, and several other symptoms that were making her life
almost unbearable.
We asked her family to record a video tape for us, to allow us to have a
better understanding of her condition and problems.
On the 15th of December 2002, she started on the first stage of our
neurogenic diet, which concentrates mainly on the replacement of any drugs that might
be causing adverse reactions.
A few weeks later, as soon as the drugs Sinemet and Amantadine were reduced
by 50%, most of the severe symptoms she was experiencing had decreased
significantly.
The family continued to video tape her over the New Year holidays and, with
great surprise, they realised that their mother was showing quick and very
dramatic improvements.
This important visual testimony helps to demonstrate that, in some
instances, the symptoms thought to be of a Parkinson’s disease condition progressing
into an MSA condition, might not be the real scenario.
Each and every food contains a tiny amount of medicinal substances which
help to heal most human diseases.
As it is written in Genesis 1.29.
"I give you every seed-bearing plant on the face of the whole earth and
every tree that has fruit with seed in it. They will be yours for food."
Based on this principle we have build up a number of research projects to
extract medicinal substances from food.
One of this is the medicinal extract RG-40.
RG-40 is an organic vegetable extract, rich in amino acids and plant kingdom
biological factors, required for the synthesis of neuronal dopamine
receptors. RG-40 natural components are organic substances which are easily allowed
to penetrate the blood brain barrier and can access the Basal Ganglia, where
they interact with the DNA of dopaminergic neurons.
RG-40 biological factors are transported inside the dopaminergic neurons
reaching the nucleus, where they interact with DNA. DNA in the cell nucleus is
the command centre where orders to carry out the synthesis of receptor
proteins are executed.
Molecular Neurobiology of Dopamine Receptor Synthesis Induced by RG-40. The
process begins in the cell nucleus, where RG-40 activates specific genes,
which induce DNA to be transcribed into messenger RNA.
Messenger RNA then travels to the endoplasmic reticulum where ribosomes
cause the messenger RNA to be translated into partially formed dopamine receptor
proteins.
The next step is for partially formed dopamine receptor proteins to be
transformed into complete dopamine receptor molecules in the Golgi Apparatus.
Completely formed dopamine receptor molecules are proteins and these are
transported to the cell membrane where they interact with the neurotransmitter
dopamine.
As a result of the interaction between the neurotransmitter dopamine and
dopamine receptor molecules, the ability of our muscular system to perform
movements is regulated. Neuronal dopamine receptor deficiency causes motor
disability problems, such as those observed in conditions like MSA-P and Parkinson's
disease.
RG-40 PROVIDES THE ORGANIC AMINO ACID PRECURSORS REQUIRED FOR THE SYNTHESIS
OF NEURONAL DOPAMINE RECEPTOR MOLECULES.
Most drugs available today to treat Parkinson's disease attempt to increase
the concentration of the neurotransmitter dopamine or its agonists in areas
of the brain which are affected in Parkinson's disease. However, the activity
of these drugs is limited by the number of neuronal dopamine receptors
available to interact with the neurotransmitter dopamine or its drug agonists.
No matter how much a patient increases the dosage of dopamine precursors
like Sinemet, or of any of the dopamine agonists drugs, if there are not enough
neuronal dopamine receptors to interact with, these drugs will not produce
any further response at all.
This figure is a schematic diagram of a dopamine receptor showing that it is
a protein arranged essentially as a long chain of amino acids.
The chain of amino acids, forming the dopamine receptor, winds in and out of
the cell several times. This creates three regions of the receptor. Firstly,
the extracellular portions are those parts of the chain entirely outside the
neuron; secondly, the intracellular portions are those segments of the chain
entirely inside the neuron and thirdly, the transmembrane portions, which
are the regions of the receptor which reside within the membrane of the neuron.
Each and all of the amino acid and biological factors required for the
synthesis of this and other dopamine receptor molecules, are present in the
organic vegetable extract RG-40, which is now used by all the PD and MSA patients
participating in our studies.
MSA-C. Olivopontocerebellar atrophy
When MSA begins with imbalance, incoordination, and difficulty in speaking
(dysarthria), it is called olivopontocerebellar atrophy; as the name suggests,
this form of MSA is marked by degeneration in the cerebellum, a structure
involved in balance and learned motor tasks.
The following patient suffers from this type of MSA, which is also called
also MSA-C because the areas affected involve the cerebellum.
Patients suffering from MSA-C usually do not show any response to the
standard parkinsonian medication. This is precisely the case of the fourth patient
presented in this video. She did not show any response to Sinemet. Moreover,
she was affected by serious side effects which are not usually present, in
the first year, in most of the patients using this drug.
We would like to suggest that this patient, as many diagnosed today with
MSA, might suffer from a high sensitivity to specific synthetic chemicals. This
chemical sensitivity might be a confusing determinant when trying to diagnose
the disease.
This patient showed rapid improvement, after using a purely organic dietary
intervention. We can assume, therefore, that she suffers from a high
sensitivity to non-organic chemicals.
This suggestion is endorsed by another experience. When this patient started
on a clinical trial for a new drug for MSA, she had to drop out at the very
beginning of the study, because of adverse reactions and innumerable side
effects. Most of the other patients in the trial were not troubled by these side
effects. The chemical sensitivity in this patient is higher than normal.
For this particular type of patient, who cannot tolerate large doses of
drugs, we need to consider prescribing organic interventions with natural
products that can help them in a similar way as with the drugs, but without adverse
reactions, that can sometimes confuse the diagnosis.
The following Parkinson's disease patients, started on our neurogenic
programme during 1998. A few months later, he decided to explore other alternatives
to treat their disease.
He was offered a treatment called: DEEP BRAIN STIMULATION

=== message truncated ===

---------------------------------
Do you Yahoo!?

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
Friends.  Fun. Try the all-new Yahoo! Messenger